Replimune Group, Inc. (REPL) is a commercial-stage biotechnology company headquartered in Woburn, Massachusetts, and founded in 2015. The company develops oncolytic immunotherapies built on its proprietary RPx platform, which uses an engineered herpes simplex virus type 1 (HSV-1) backbone to destroy tumors directly while aiming to stimulate a systemic anti-tumor immune response.
Its lead product, TUDRIQEV (vusolimogene oderparepvec-wtpg), received FDA accelerated approval on August 6, 2026, for use in combination with Bristol Myers Squibb's (BMY) Opdivo (nivolumab) to treat adults with unresectable advanced cutaneous melanoma that has progressed after anti-PD-1 therapy. The company is also advancing earlier-stage candidates RP2 and RP3 across additional oncology indications. Replimune competes with other advanced-melanoma therapies, including Iovance Biotherapeutics' (IOVA) Amtagvi.
Over the trailing 30 days, REPL advanced approximately +62.7%, rising from an adjusted close of $11.72 on October 21, 2026, to $19.07 on November 20, 2026. The rally accelerated in late October following the company's quarterly report, with the stock reaching an intraday high near $23.41 on November 10 before profit-taking pulled it back to the high-teens by mid-November. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The broader quarterly trend tells a similar but more volatile story. Three months earlier, on August 20, 2026, REPL closed at $14.05, meaning the stock gained roughly +36% over the full quarter. That performance, however, was not linear: shares spiked into the mid-teens immediately after the August FDA approval, drifted down to about $10.86 by mid-October, and then surged again on early launch data and second-quarter results.
The primary catalyst was the commercial launch of TUDRIQEV, which became available in the United States on October 1, 2026. Early adoption metrics were encouraging: by late October, Replimune reported that roughly 20 melanoma institutions had added the therapy to their formularies and more than 15 had begun prescribing and treating patients. These figures signaled real-world demand and validated the company's transition from a clinical-stage to a commercial-stage business.
Fiscal second-quarter 2027 results, released on October 28, added further support. Replimune reported a net loss of $57.1 million, or $0.54 per share, narrowing from $83.1 million, or $0.90 per share, a year earlier and beating consensus estimates. The company ended the quarter with $307.8 million in cash and equivalents, which it said would fund operations for more than twelve months.
Analyst activity reinforced the move. On November 16, Piper Sandler raised its price target on REPL to $27 from $14 while maintaining an Overweight rating, and other firms issued targets in the high-$20s to low-$30s. Elevated short interest—reported near 34% of the free float—along with a broader rotation into high-beta biotech names likely added squeeze-related momentum during the rally.
The quarterly trend was shaped by a decisive regulatory turnaround. After receiving two FDA Complete Response Letters for its biologics license application—in July 2025 and again in April 2026—Replimune secured accelerated approval for TUDRIQEV on August 6, 2026. The approval was based on the anti-PD-1-failed melanoma cohort of the IGNYTE trial, which showed an objective response rate of 24.2% and a median duration of response of 14.1 months.
That milestone followed a difficult restructuring announced in April 2026 that included a workforce reduction of approximately 55%. In August, Replimune strengthened its balance sheet through a public offering that raised net proceeds of approximately $141 million at $12.06 per share, and in September it drew an additional $15 million under its loan facility. The subsequent commercial launch of TUDRIQEV completed the company's shift toward revenue generation, providing the broader narrative behind the quarter's gains.
Investors monitoring REPL should focus on the pace of TUDRIQEV's commercial uptake, including the number of prescribing institutions, reimbursement decisions, and participation in programs such as the 340B drug pricing program. Competitive dynamics with Iovance's Amtagvi will also be important, as physicians weigh the two approved post-PD-1 melanoma options.
The confirmatory Phase 3 IGNYTE-3 trial remains the most significant regulatory risk, since continued approval of TUDRIQEV depends on verification of clinical benefit. Progress on the RP2 pipeline—including the REVEAL study in metastatic uveal melanoma and a combination study in hepatocellular carcinoma—could expand the company's addressable market. Finally, cash burn, potential future financing, and broader biotech sentiment are factors that may influence near-term price action. These items are informational considerations, not investment recommendations.
In my research process, I often look at Tickeron’s AI Trading Bots to see how systematic strategies are handling volatile names like this one. The platform hosts hundreds of AI-driven bots across thousands of tickers, and the trending section highlights those with strong recent results. It offers a useful way to compare different holding periods and methodologies without relying on any single approach.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
REPL moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend. In 28 of 31 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for REPL crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +7.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where REPL advanced for three days, in 183 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Aroon Indicator entered an Uptrend today. In 175 of 218 cases where REPL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
The 10-day RSI Indicator for REPL moved out of overbought territory on November 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 19 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 79%.
The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on REPL as a result. In 67 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Moving Average Convergence Divergence Histogram (MACD) for REPL turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 39 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where REPL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
REPL broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. REPL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.282) is normal, around the industry mean (3.596). P/E Ratio (-6.863) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REPL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of oncolytic immunotherapies
Industry Biotechnology